查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1629905

全球医药冷链物流市场 - 2025-2033

Global Pharmaceutical Cold Chain Logistics Market - 2025-2033
出版日期: | 出版商: DataM Intelligence | 英文 179 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

全球医药冷链物流市场2024年达186亿美元，预计2033年将达271亿美元，2025-2033年预测期间复合年增长率为4.3%。

药品冷链物流是指在整个供应链中管理、储存和运输对温度敏感的药品（例如疫苗、生物製品和其他需要严格温度控制以保持其有效性和安全性的医药产品）的专门过程。药品冷链物流涉及对温度敏感的药品从製造到最终交付给最终用户的整个生命週期的管理。此物流系统包括温控储存、运输、包装、即时监控和追踪。

过去十年，医药冷链物流经历了快速创新与发展。对生物製品和其他温度敏感药物的需求不断增长，增加了对可靠的温控分配系统的需求。例如，根据美国国立卫生研究院的数据，近年来，生物製剂占核准药物总量的比例不足30%。 2000 年代初，在行业专家共同努力提高认识和标准化最佳实践的推动下，出现了对冷链物流的专门关注。

市场动态：

驱动程式和限制

冷链技术不断进步

冷链技术的不断进步极大地推动了药品冷链物流市场的成长，预计将在预测期内推动该市场的发展。支援物联网的解决方案透过即时监控运输和储存过程中的环境条件，彻底改变了冷链物流。这些系统使用感测器持续追踪温度、湿度和其他条件，提醒物流提供者任何偏差。这确保了药品的完整性，特别是对温度变化敏感的疫苗和生物製剂。

例如，2024 年 2 月，Sensitech 推出了 TempTale GEO X，这是一款专为生命科学产业和物流组织量身定制的创新物联网温度监测解决方案。这项尖端解决方案旨在为全球透过航空、海运、公路和铁路等各种运输方式运输的温度敏感药物和疫苗提供即时监控和分析。 TempTale GEO X 代表在增强药品供应链冷链合规性、供应链效率和永续性成果方面向前迈出了重要一步。

此外，2022 年 9 月，新创公司 CubeWorks 透过突破性的智慧感测解决方案加速物联网的未来，推出了新一代冷链物流视觉化解决方案 CubiSens XT1。 XT1 是同类中首款温度追踪器，能够对生物製药产品进行产品级监控，以确保整个生命週期的温度合规性和品质保证。 CubiSens XT1 的直径仅 16 毫米，比传统资料记录仪小 100 倍，足够小，足以安装在任何需要温度监控的单一产品上。

自动化系统正在整合到冷链物流中，用于分类、处理和储存对温度敏感的药品。这些技术降低了人为错误的风险，提高了效率，并改善了 GDP 法规的合规性。例如，2024 年 6 月，主动供应链风险管理和情报领域的全球领导者 Overhaul 推出了其尖端的冷链品质解决方案。这项创新的软体解决方案为时间和温度敏感的货物提供无与伦比的风险和品质管理，确保製药、医疗保健和高价值食品和饮料行业的整个供应链处于最佳状态。

监管挑战

监理挑战是医药冷链物流市场成长的重大障碍。良好分销规范 (GDP) 和良好製造规范 (GMP) 等严格法规要求高水准的合规性，其中包括在储存和运输过程中保持适当的温度控制。由于需要专门的设备、设施和人员，这些标准的实施和维护成本高昂。

例如，FDA 的 GDP 指南要求对药品的温控运输进行严格的记录和监控。遵守这些准则需要对技术和基础设施进行大量投资，这可能对小型物流提供者构成障碍。

不同地区有不同的监管要求。在美国，FDA 主要透过良好分销规范 (GDP) 和现行良好生产规范 (cGMP) 提供全面的冷链管理指南。这些法规确保药品在适当的条件下储存、处理和运输，以维持其安全性、有效性和品质。欧洲药品管理局 (EMA) 对欧盟境内的药品分销制定了严格的冷链要求。这种不一致使物流管理变得复杂，尤其是对于全球营运而言。

监管机构会对不合规的公司处以巨额罚款和製裁，例如温度超出范围会损坏药品。这些处罚可能很严厉，导致经济损失和声誉受损。例如，由于温度处理不当而导致的产品召回可能会给公司带来数百万美元的销售损失、法律费用以及品牌声誉受损。

目录

第一章：市场介绍和范围

  • 报告的目标
  • 报告范围和定义
  • 报告范围

第 2 章：高阶主管见解与要点

  • 市场亮点和战略要点
  • 主要趋势和未来预测
  • 按产品类型分類的片段
  • 按服务类型分類的片段
  • 按温度范围分類的片段
  • 按交付方式分類的片段
  • 最终使用者的片段
  • 按地区分類的片段

第 3 章：动力学

  • 影响因素
    • 司机
      • 冷链技术不断进步
      • 虚拟控制塔和即时追踪
    • 限制
      • 监管挑战
    • 机会
    • 影响分析

第 4 章：策略洞察与产业展望

  • 市场领导者和先驱
    • 新兴先锋和杰出参与者
    • 拥有最大销售品牌的知名领导者
    • 拥有成熟产品的市场领导者
  • 新兴新创企业和关键创新者
  • CXO 观点
  • 最新进展和突破
  • 案例研究/正在进行的研究
  • 监管和报销情况
    • 北美洲
    • 欧洲
    • 亚太地区
    • 拉丁美洲
    • 中东和非洲
  • 波特五力分析
  • 供应链分析
  • 专利分析
  • SWOT分析
  • 未满足的需求和差距
  • 市场进入和扩张的推荐策略
  • 情境分析：最佳情况、基本情况和最坏情况预测
  • 定价分析和价格动态

第 5 章：药品冷链物流市场，依产品类型

  • 疫苗
  • 生物製药
  • 药品和药品

第 6 章：药品冷链物流市场（依服务类型）

  • 贮存
  • 运输
  • 包装
  • 其他的

第 7 章：药品冷链物流市场（依温度范围）

  • 冷冻（-20°C以下）
  • 冷藏（2°C 至 8°C）
  • 环境温度（15°C 至 25°C）
  • 低温（-150°C）

第 8 章：药品冷链物流市场（以交付方式）

  • 最后一哩交付
  • 集线器到经销商

第 9 章：药品冷链物流市场（依最终用户）

  • 製药和生物製药公司
  • 生技公司
  • 医院和医疗机构
  • 其他的

第 10 章：医药冷链物流市场，按区域市场分析与成长机会

  • 北美洲
    • 我们
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 法国
    • 西班牙
    • 义大利
    • 欧洲其他地区
  • 南美洲
    • 巴西
    • 阿根廷
    • 南美洲其他地区
  • 亚太
    • 中国
    • 印度
    • 日本
    • 韩国
    • 亚太其他地区
  • 中东和非洲

第 11 章：竞争格局与市场定位

  • 竞争概况和主要市场参与者
  • 市占率分析与定位矩阵
  • 策略伙伴关係、併购
  • 产品组合和创新的主要发展
  • 公司基准化分析

第 12 章：公司简介

  • Cardinal Health
    • 公司概况
    • 产品组合和描述
    • 财务概览
    • 主要进展
    • SWOT分析
  • AmerisourceBergen Corporation
  • Envirotainer AB
  • FedEx
  • United Parcel Service of America, Inc.
  • Thermo King
  • Sonoco ThermoSafe
  • B Medical Systems India Private Limited
  • DoKaSch TEMPERATURE SOLUTIONS GmbH
  • Nordic Cold Chain Solutions

第 13 章：假设与研究方法

  • 资料收集方法
  • 数据三角测量
  • 预测技术
  • 数据验证和确认

第 14 章：附录

简介目录
Product Code: PH8935

The global pharmaceutical cold chain logistics market reached US$ 18.6 billion in 2024 and is expected to reach US$ 27.1 billion by 2033, growing at a CAGR of 4.3% during the forecast period 2025-2033.

Pharmaceutical cold chain logistics refers to the specialized process of managing, storing and transporting temperature-sensitive pharmaceutical products such as vaccines, biologics and other medicinal products that require strict temperature controls to maintain their efficacy and safety throughout the supply chain. Pharmaceutical cold chain logistics involves the management of the entire lifecycle of temperature-sensitive pharmaceutical products from manufacturing through to the final delivery to the end-user. This logistics system includes temperature-controlled storage, transportation, packaging, real-time monitoring and tracking.

In the past decade, pharmaceutical cold chain logistics has experienced rapid innovation and growth. The increasing demand for biologics and other temperature-sensitive medicines has heightened the need for reliable, temperature-controlled distribution systems. For instance, according to the National Institute of Health, in recent years, biologics have accounted for less than 30% of the total drugs approved. In the early 2000s, a specialized focus on cold chain logistics emerged, driven by a collaborative effort among industry experts to promote awareness and standardize best practices.

Market Dynamics: Drivers & Restraints

Rising advancements in cold chain technology

The rising advancements in cold chain technology are significantly driving the growth of the Pharmaceutical Cold Chain Logistics market and are expected to drive the market over the forecast period. IoT-enabled solutions have revolutionized cold chain logistics by providing real-time monitoring of environmental conditions during transport and storage. These systems use sensors to continuously track temperature, humidity, and other conditions, alerting logistics providers to any deviations. This ensures the integrity of pharmaceutical products, especially vaccines and biologics, which are sensitive to temperature changes.

For instance, in February 2024, Sensitech introduced TempTale GEO X, an innovative IoT temperature monitoring solution tailored specifically for the life sciences industry and logistics organizations. This cutting-edge solution is designed to deliver real-time monitoring and analytics for temperature-sensitive medicines and vaccines transported globally across various modes of transportation, including air, ocean, road, and rail. TempTale GEO X represents a significant step forward in enhancing cold chain compliance, supply chain efficiency, and sustainability outcomes in the pharmaceutical supply chain.

Additionally, in September 2022, CubeWorks, a startup company accelerating the future of IoT through breakthrough smart sensing solutions, introduced the next-generation visibility solution for cold chain logistics with the CubiSens XT1. The XT1 is the first temperature tracker of its kind that enables product-level monitoring of biopharma products for temperature compliance and quality assurance for the entire lifecycle. Measuring a mere 16 mm in diameter, the CubiSens XT1 is 100x smaller than conventional data loggers, small enough to fit on any individual product that requires temperature monitoring.

Automated systems are being integrated into cold chain logistics for sorting, handling, and storing temperature-sensitive pharmaceuticals. These technologies reduce the risk of human error, enhance efficiency, and improve compliance with GDP regulations. For instance, in June 2024, Overhaul, a global leader in active supply chain risk management and intelligence, launched its cutting-edge Cold Chain Quality Solution. This innovative software solution delivers unparalleled risk and quality management for time and temperature-sensitive cargo, ensuring optimal conditions throughout the supply chain for the pharmaceutical, healthcare and high-value food and beverage sectors.

Regulatory challenges

Regulatory challenges are a significant barrier to the growth of the pharmaceutical cold chain logistics market. Stringent regulations such as Good Distribution Practice (GDP) and Good Manufacturing Practice (GMP) require high levels of compliance, which includes maintaining proper temperature controls during storage and transportation. These standards are expensive to implement and maintain due to the need for specialized equipment, facilities, and personnel.

For instance, the FDA's GDP guidelines mandate strict documentation and monitoring of temperature-controlled shipments for pharmaceuticals. Compliance with these guidelines requires significant investments in technology and infrastructure, which can be a barrier for smaller logistics providers.

Different regions have different regulatory requirements. In the United States, the FDA provides comprehensive guidelines for cold chain management, primarily through the Good Distribution Practices (GDP) and current Good Manufacturing Practices (cGMP). These regulations ensure that pharmaceutical products are stored, handled, and transported under appropriate conditions to maintain their safety, efficacy, and quality. The European Medicines Agency (EMA) sets out strict cold chain requirements for pharmaceutical distribution within the European Union. This inconsistency complicates logistics management, especially for global operations.

Regulatory bodies impose heavy fines and sanctions on companies for non-compliance, such as temperature excursions that damage pharmaceutical products. These penalties can be severe, leading to financial losses and reputational damage. For instance, a product recall due to temperature mishandling could cost a company millions in lost sales, legal fees, and damage to its brand reputation.

Segment Analysis

The global pharmaceutical cold chain logistics market is segmented based on product type, service type, temperature range, mode of delivery, end-user and region.

Temperature Range:

The cryogenic segment is expected to dominate the pharmaceutical cold chain logistics market share

The demand for Cryogenic conditions (temperatures typically below -150°C) is usually high as these are essential for transporting and storing advanced biopharmaceutical products such as mRNA vaccines, gene therapies and CAR-T cell therapies. These products are highly sensitive to temperature variations, necessitating ultra-low temperature logistics to maintain their stability and efficacy.

For instance, in April 2024, CSafe launched three new technologies building on its portfolio of solutions integrating real-time data tracking to ensure maximum visibility throughout the shipping journey. CSafe's Multi-Use Dewars, the first in the CGT Cryo Series, are designed to serve the growing cell and gene therapy market. These cryogenic, reusable dewars maintain the coldest temperature range of -150°C or colder. This technology uses liquid nitrogen dry vapor units and includes a built-in TracSafe RLT real-time data tracking device.

Technological advancements have made cryogenic logistics more efficient and reliable. The development of advanced cryogenic packaging solutions, including passive cooling technologies like phase change materials and insulated containers, has improved the ability to maintain ultra-low temperatures for longer periods, especially during transit.

Geographical Analysis

North America is expected to hold a significant position in the Pharmaceutical Cold Chain Logistics market share

North America, particularly the United States and Canada, boasts a highly developed healthcare system with a significant demand for biologics, vaccines and temperature-sensitive pharmaceuticals. The region's advanced cold chain infrastructure, including a vast network of refrigerated warehouses and transportation facilities, ensures that products remain stable from manufacturer to patient.

For instance, in six years, NewCold has gone from zero to three of the most advanced temperature-controlled warehouses in the United States, with a fourth set to become operational in mid-2024. January 18, 2024 marks six years since the first pallet was received in 2018. At the time of its founding, NewCold Tacoma was considered one of the most energy-efficient and technologically advanced North American automated warehouses in the United States.

North America leads globally in the demand for biopharmaceuticals such as vaccines, biologics, and advanced therapies. This demand drives the growth of the cold chain logistics market as these products require ultra-low temperatures during transit and storage. For instance, according to the National Institute of Health (NIH), U.S. vaccine sales are estimated to be about $1.5 billion per year.

North America is a hub for cold chain technology innovation. The region is at the forefront of developing advanced logistics technologies such as IoT-enabled real-time temperature monitoring, automated warehouses, and cryogenic packaging solutions. These advancements enhance the efficiency and reliability of cold chain logistics.

For instance, Sensitech introduced TempTale GEO X, an innovative IoT temperature monitoring solution tailored specifically for the life sciences industry and logistics organizations. This cutting-edge solution is designed to deliver real-time monitoring and analytics for temperature-sensitive medicines and vaccines transported globally across various modes of transportation, including air, ocean, road, and rail. TempTale GEO X represents a significant step forward in enhancing cold chain compliance, supply chain efficiency, and sustainability outcomes in the pharmaceutical supply chain.

Asia-Pacific is growing at the fastest pace in the Pharmaceutical Cold Chain Logistics market

The Asia-Pacific region is rapidly improving its cold chain logistics infrastructure, with investments in refrigerated warehouses, transportation networks, and technology upgrades such as real-time monitoring systems. Countries like China and India are particularly active in expanding their cold chain networks to support the growing demand for temperature-sensitive pharmaceuticals.

For instance, in October 2024, UPS launched its specialized healthcare-focused cross-docking facility in Hyderabad. The facility is designed as a pharma-grade facility and comes with global freight forwarding capabilities. Providing an additional layer of security for temperature-controlled pharmaceutical shipments, it can hold or sort 15 pallets at +15°C to +25°C, 7 Pallets at +2 to +8°C and 50 pallets under uncontrolled ambient conditions. This enables pharma companies to distribute their products more efficiently, eliminating the need for prolonged warehouse storage.

Competitive Landscape

The major global players in the pharmaceutical cold chain logistics market include Cardinal Health, AmerisourceBergen Corporation, Envirotainer AB, FedEx, United Parcel Service of America, Inc., Thermo King, Sonoco ThermoSafe, B Medical Systems India Private Limited, DoKaSch TEMPERATURE SOLUTIONS GmbH, Nordic Cold Chain Solutions and among others.

The Growth and Future of Pharmaceutical Cold Chain Logistics

  • The pharmaceutical cold chain market has experienced rapid growth over the past decade, often outpacing the pharmaceutical industry itself. Cold chain shipments have consistently grown at a rate double that of the industry overall. However, recent years have seen a slight plateau, driven in part by a decline in new FDA drug approvals. Despite this, emerging therapies, biosimilars, and the ongoing demand for biologics continue to fuel the growth of the pharmaceutical cold chain.
  • In particular, the introduction of biosimilars, such as those targeting Humira (adalimumab), a blockbuster biologic, has opened up new opportunities for the cold chain logistics market. As more biologics face competition from biosimilars, the logistics industry is poised to meet the growing demand for temperature-controlled shipping, ensuring that these products are delivered safely and efficiently.
  • Another key trend influencing the future of the pharmaceutical cold chain is the increasing reliance on home delivery services for healthcare and pharmaceuticals. Companies like UPS Healthcare are expanding their offerings in home delivery, a trend accelerated by the COVID-19 pandemic. With the continued growth of e-commerce and home-based healthcare, the demand for cold chain logistics in home delivery will continue to rise, presenting new challenges and opportunities for logistics providers.

Why Purchase the Report?

  • Pipeline & Innovations: Reviews ongoing clinical trials, product pipelines, and forecasts upcoming advancements in medical devices and pharmaceuticals.
  • Product Performance & Market Positioning: Analyzes product performance, market positioning, and growth potential to optimize strategies.
  • Real-World Evidence: Integrates patient feedback and data into product development for improved outcomes.
  • Physician Preferences & Health System Impact: Examines healthcare provider behaviors and the impact of health system mergers on adoption strategies.
  • Market Updates & Industry Changes: Covers recent regulatory changes, new policies, and emerging technologies.
  • Competitive Strategies: Analyzes competitor strategies, market share, and emerging players.
  • Pricing & Market Access: Reviews pricing models, reimbursement trends, and market access strategies.
  • Market Entry & Expansion: Identifies optimal strategies for entering new markets and partnerships.
  • Regional Growth & Investment: Highlights high-growth regions and investment opportunities.
  • Supply Chain Optimization: Assesses supply chain risks and distribution strategies for efficient product delivery.
  • Sustainability & Regulatory Impact: Focuses on eco-friendly practices and evolving regulations in healthcare.
  • Post-market Surveillance: Uses post-market data to enhance product safety and access.
  • Pharmacoeconomics & Value-Based Pricing: Analyzes the shift to value-based pricing and data-driven decision-making in R&D.

The global pharmaceutical cold chain logistics market report delivers a detailed analysis with 62 key tables, more than 52 visually impactful figures, and 179 pages of expert insights, providing a complete view of the market landscape.

Target Audience 2023

  • Manufacturers: Pharmaceutical, Medical Device, Biotech Companies, Contract Manufacturers, Distributors, Hospitals.
  • Regulatory & Policy: Compliance Officers, Government, Health Economists, Market Access Specialists.
  • Technology & Innovation: AI/Robotics Providers, R&D Professionals, Clinical Trial Managers, Pharmacovigilance Experts.
  • Investors: Healthcare Investors, Venture Fund Investors, Pharma Marketing & Sales.
  • Consulting & Advisory: Healthcare Consultants, Industry Associations, Analysts.
  • Supply Chain: Distribution and Supply Chain Managers.
  • Consumers & Advocacy: Patients, Advocacy Groups, Insurance Companies.
  • Academic & Research: Academic Institutions.

Table of Contents

1. Market Introduction and Scope

  • 1.1. Objectives of the Report
  • 1.2. Report Coverage & Definitions
  • 1.3. Report Scope

2. Executive Insights and Key Takeaways

  • 2.1. Market Highlights and Strategic Takeaways
  • 2.2. Key Trends and Future Projections
  • 2.3. Snippet by Product Type
  • 2.4. Snippet by Service Type
  • 2.5. Snippet by Temperature Range
  • 2.6. Snippet by Mode of Delivery
  • 2.7. Snippet by End-User
  • 2.8. Snippet by Region

3. Dynamics

  • 3.1. Impacting Factors
    • 3.1.1. Drivers
      • 3.1.1.1. Rising Advancements in Cold Chain Technology
      • 3.1.1.2. Virtual Control Towers and Real-Time Tracking
    • 3.1.2. Restraints
      • 3.1.2.1. Regulatory Challenges
    • 3.1.3. Opportunity
    • 3.1.4. Impact Analysis

4. Strategic Insights and Industry Outlook

  • 4.1. Market Leaders and Pioneers
    • 4.1.1. Emerging Pioneers and Prominent Players
    • 4.1.2. Established leaders with largest selling Brand
    • 4.1.3. Market leaders with established Product
  • 4.2. Emerging Startups and Key Innovators
  • 4.3. CXO Perspectives
  • 4.4. Latest Developments and Breakthroughs
  • 4.5. Case Studies/Ongoing Research
  • 4.6. Regulatory and Reimbursement Landscape
    • 4.6.1. North America
    • 4.6.2. Europe
    • 4.6.3. Asia Pacific
    • 4.6.4. Latin America
    • 4.6.5. Middle East & Africa
  • 4.7. Porter's Five Force Analysis
  • 4.8. Supply Chain Analysis
  • 4.9. Patent Analysis
  • 4.10. SWOT Analysis
  • 4.11. Unmet Needs and Gaps
  • 4.12. Recommended Strategies for Market Entry and Expansion
  • 4.13. Scenario Analysis: Best-Case, Base-Case, and Worst-Case Forecasts
  • 4.14. Pricing Analysis and Price Dynamics

5. Pharmaceutical Cold Chain Logistics Market, By Product Type

  • 5.1. Introduction
    • 5.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 5.1.2. Market Attractiveness Index, By Product Type
  • 5.2. Vaccines*
    • 5.2.1. Introduction
    • 5.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 5.3. Biopharmaceuticals
  • 5.4. Drugs and Medicines

6. Pharmaceutical Cold Chain Logistics Market, By Service Type

  • 6.1. Introduction
    • 6.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 6.1.2. Market Attractiveness Index, By Service Type
  • 6.2. Storage*
    • 6.2.1. Introduction
    • 6.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 6.3. Transportation
  • 6.4. Packaging
  • 6.5. Others

7. Pharmaceutical Cold Chain Logistics Market, By Temperature Range

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 7.1.2. Market Attractiveness Index, By Temperature Range
  • 7.2. Frozen (Below -20°C) *
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 7.3. Refrigerated (2°C to 8°C)
  • 7.4. Ambient (15°C to 25°C)
  • 7.5. Cryogenic (-150°C)

8. Pharmaceutical Cold Chain Logistics Market, By Mode of Delivery

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 8.1.2. Market Attractiveness Index, By Mode of Delivery
  • 8.2. Last-Mile Delivery *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 8.3. Hubs-to-Distributor

9. Pharmaceutical Cold Chain Logistics Market, By End-User

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 9.1.2. Market Attractiveness Index, By End-User
  • 9.2. Pharmaceutical and Biopharmaceutical Companies*
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
  • 9.3. Biotechnology Companies
  • 9.4. Hospitals and Healthcare Facilities
  • 9.5. Others

10. Pharmaceutical Cold Chain Logistics Market, By Regional Market Analysis and Growth Opportunities

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.2.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.2.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.2.8.1. U.S.
      • 10.2.8.2. Canada
      • 10.2.8.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.3.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.3.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.3.8.1. Germany
      • 10.3.8.2. U.K.
      • 10.3.8.3. France
      • 10.3.8.4. Spain
      • 10.3.8.5. Italy
      • 10.3.8.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.4.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.4.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.4.8.1. Brazil
      • 10.4.8.2. Argentina
      • 10.4.8.3. Rest of South America
  • 10.5. Asia-Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.5.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User
    • 10.5.8. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
      • 10.5.8.1. China
      • 10.5.8.2. India
      • 10.5.8.3. Japan
      • 10.5.8.4. South Korea
      • 10.5.8.5. Rest of Asia-Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Product Type
    • 10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Service Type
    • 10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Temperature Range
    • 10.6.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Mode of Delivery
    • 10.6.7. Market Size Analysis and Y-o-Y Growth Analysis (%), By End-User

11. Competitive Landscape and Market Positioning

  • 11.1. Competitive Overview and Key Market Players
  • 11.2. Market Share Analysis and Positioning Matrix
  • 11.3. Strategic Partnerships, Mergers & Acquisitions
  • 11.4. Key Developments in Product Portfolios and Innovations
  • 11.5. Company Benchmarking

12. Company Profiles

  • 12.1. Cardinal Health*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Financial Overview
    • 12.1.4. Key Developments
    • 12.1.5. SWOT Analysis
  • 12.2. AmerisourceBergen Corporation
  • 12.3. Envirotainer AB
  • 12.4. FedEx
  • 12.5. United Parcel Service of America, Inc.
  • 12.6. Thermo King
  • 12.7. Sonoco ThermoSafe
  • 12.8. B Medical Systems India Private Limited
  • 12.9. DoKaSch TEMPERATURE SOLUTIONS GmbH
  • 12.10. Nordic Cold Chain Solutions

LIST NOT EXHAUSTIVE

13. Assumption and Research Methodology

  • 13.1. Data Collection Methods
  • 13.2. Data Triangulation
  • 13.3. Forecasting Techniques
  • 13.4. Data Verification and Validation

14. Appendix

  • 14.1. About Us and Services
  • 14.2. Contact Us